Abstract
Invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) most commonly affects infants,1,2 but a vaccine has long eluded vaccinologists. The main barrier has been the B polysaccharide. The serogroup A, C, W-135, and Y polysaccharides are highly immunogenic and licensed vaccines are available. By contrast, the group B polysaccharide has antigenic similarities with glycoproteins expressed by fetal neural tissue that render it non-immunogenic in human beings.3 The novel multicomponent protein-based vaccine against MenB, 4CMenB, circumvents this barrier with a cocktail of three surface-expressed protein antigens: factor-H-binding protein variant 1, neisserial heparin-binding antigen, and neisserial adhesin A.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
